FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988293081> ?p ?o ?g. }

• W1988293081 endingPage "2120" @default.
• W1988293081 startingPage "2112" @default.
• W1988293081 abstract "Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR-ABL inhibitor, nilotinib (AMN107), is significantly more potent against BCR-ABL than imatinib, and is active against many imatinib-resistant BCR-ABL mutants. Phase 1/2 clinical trials show that nilotinib can induce remissions in patients who have previously failed imatinib, indicating that sequential therapy with these 2 agents has clinical value. However, simultaneous, rather than sequential, administration of 2 BCR-ABL kinase inhibitors is attractive for many reasons, including the theoretical possibility that this could reduce emergence of drug-resistant clones. Here, we show that exposure of a variety of BCR-ABL+ cell lines to imatinib and nilotinib results in additive or synergistic cytotoxicity, including testing of a large panel of cells expressing BCR-ABL point mutations causing resistance to imatinib in patients. Further, using a highly quantifiable bioluminescent in vivo model, drug combinations were at least additive in antileukemic activity, compared with each drug alone. These results suggest that despite binding to the same site in the same target kinase, the combination of imatinib and nilotinib is highly efficacious in these models, indicating that clinical testing of combinations of BCR-ABL kinase inhibitors is warranted." @default.
• W1988293081 created "2016-06-24" @default.
• W1988293081 creator A5000144262 @default.
• W1988293081 creator A5009750077 @default.
• W1988293081 creator A5011479527 @default.
• W1988293081 creator A5013829081 @default.
• W1988293081 creator A5016985690 @default.
• W1988293081 creator A5028072503 @default.
• W1988293081 creator A5039503690 @default.
• W1988293081 creator A5041834110 @default.
• W1988293081 creator A5045142166 @default.
• W1988293081 creator A5055853326 @default.
• W1988293081 creator A5059247439 @default.
• W1988293081 creator A5076565130 @default.
• W1988293081 creator A5079183684 @default.
• W1988293081 creator A5082263317 @default.
• W1988293081 creator A5090097432 @default.
• W1988293081 date "2006-10-26" @default.
• W1988293081 modified "2023-09-29" @default.
• W1988293081 title "Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias" @default.
• W1988293081 cites W120419820 @default.
• W1988293081 cites W1964261631 @default.
• W1988293081 cites W1980060129 @default.
• W1988293081 cites W1981709629 @default.
• W1988293081 cites W1983999811 @default.
• W1988293081 cites W1999614615 @default.
• W1988293081 cites W2002777245 @default.
• W1988293081 cites W2016086822 @default.
• W1988293081 cites W2016656445 @default.
• W1988293081 cites W2020164940 @default.
• W1988293081 cites W2028959752 @default.
• W1988293081 cites W2054251966 @default.
• W1988293081 cites W2061860992 @default.
• W1988293081 cites W2066998725 @default.
• W1988293081 cites W2067652212 @default.
• W1988293081 cites W2069153761 @default.
• W1988293081 cites W2074740152 @default.
• W1988293081 cites W2077945404 @default.
• W1988293081 cites W2092606584 @default.
• W1988293081 cites W2097946794 @default.
• W1988293081 cites W2113344287 @default.
• W1988293081 cites W2124196948 @default.
• W1988293081 cites W2131067167 @default.
• W1988293081 cites W2131174104 @default.
• W1988293081 cites W2131476854 @default.
• W1988293081 cites W2131501125 @default.
• W1988293081 cites W2142969636 @default.
• W1988293081 cites W2147537382 @default.
• W1988293081 cites W2159863363 @default.
• W1988293081 cites W2172629038 @default.
• W1988293081 cites W2411151142 @default.
• W1988293081 cites W2523466272 @default.
• W1988293081 cites W2555977518 @default.
• W1988293081 cites W2593539765 @default.
• W1988293081 cites W4238637926 @default.
• W1988293081 cites W4254223376 @default.
• W1988293081 cites W4256436782 @default.
• W1988293081 doi "https://doi.org/10.1182/blood-2006-06-026377" @default.
• W1988293081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1801049" @default.
• W1988293081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17068153" @default.
• W1988293081 hasPublicationYear "2006" @default.
• W1988293081 type Work @default.
• W1988293081 sameAs 1988293081 @default.
• W1988293081 citedByCount "94" @default.
• W1988293081 countsByYear W19882930812012 @default.
• W1988293081 countsByYear W19882930812013 @default.
• W1988293081 countsByYear W19882930812014 @default.
• W1988293081 countsByYear W19882930812015 @default.
• W1988293081 countsByYear W19882930812016 @default.
• W1988293081 countsByYear W19882930812018 @default.
• W1988293081 countsByYear W19882930812019 @default.
• W1988293081 countsByYear W19882930812020 @default.
• W1988293081 countsByYear W19882930812021 @default.
• W1988293081 countsByYear W19882930812022 @default.
• W1988293081 countsByYear W19882930812023 @default.
• W1988293081 crossrefType "journal-article" @default.
• W1988293081 hasAuthorship W1988293081A5000144262 @default.
• W1988293081 hasAuthorship W1988293081A5009750077 @default.
• W1988293081 hasAuthorship W1988293081A5011479527 @default.
• W1988293081 hasAuthorship W1988293081A5013829081 @default.
• W1988293081 hasAuthorship W1988293081A5016985690 @default.
• W1988293081 hasAuthorship W1988293081A5028072503 @default.
• W1988293081 hasAuthorship W1988293081A5039503690 @default.
• W1988293081 hasAuthorship W1988293081A5041834110 @default.
• W1988293081 hasAuthorship W1988293081A5045142166 @default.
• W1988293081 hasAuthorship W1988293081A5055853326 @default.
• W1988293081 hasAuthorship W1988293081A5059247439 @default.
• W1988293081 hasAuthorship W1988293081A5076565130 @default.
• W1988293081 hasAuthorship W1988293081A5079183684 @default.
• W1988293081 hasAuthorship W1988293081A5082263317 @default.
• W1988293081 hasAuthorship W1988293081A5090097432 @default.
• W1988293081 hasBestOaLocation W19882930811 @default.
• W1988293081 hasConcept C121608353 @default.
• W1988293081 hasConcept C125418893 @default.
• W1988293081 hasConcept C126322002 @default.
• W1988293081 hasConcept C170493617 @default.
• W1988293081 hasConcept C2776960273 @default.
• W1988293081 hasConcept C2777413986 @default.

• next